[1] S. Oliveto, M. Mancino, N. Manfrini and S. Biffo. Role of microRNAs in translation regulation and cancer. World J. Biol. Chem. 8(1), pp. 45–56. 2017. DOI: 10.4331/wjbc.v8.i1.45.
[2] M. Garofalo and C. M. Croce. Role of microRNAs in maintaining cancer stem cells. Adv. Drug Deliv. Rev. 81pp. 53–61. 2015. DOI: 10.1016/j.addr.2014.11.014.
[3] C. H. Liu, J. Ampuero, A. Gil-Gomez, R. Montero-Vallejo, A. Rojas, R. Munoz-Hernandez, R. Gallego-Duran and M. Romero-Gomez. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 69(6), pp. 1335–1348. 2018. DOI: S0168–8278(18)32289-X.
[4] X. Wang, Z. Liao, Z. Bai, Y. He, J. Duan and L. Wei. MiR–93–5p promotes cell proliferation through down-regulating PPARGC1A in hepatocellular carcinoma cells by bioinformatics analysis and experimental verification. Genes (Basel) 9(1), pp. 10.3390/genes9010051. 2018. DOI: E51.
[5] E. Enerly, I. Steinfeld, K. Kleivi, S. K. Leivonen, M. R. Aure, H. G. Russnes, J. A. Ronneberg, H. Johnsen, R. Navon, E. Rodland, R. Makela, B. Naume, M. Perala, O. Kallioniemi, V. N. Kristensen, Z. Yakhini and A. L. Borresen-Dale. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 6(2), pp. e16915. 2011. DOI: 10.1371/journal.pone.0016915.
[6] B. D. Wang, K. Ceniccola, Q. Yang, R. Andrawis, V. Patel, Y. Ji, J. Rhim, J. Olender, A. Popratiloff, P. Latham, Y. Lai, S. R. Patierno and N. H. Lee. Identification and functional validation of reciprocal microRNA-mRNA pairings in african american prostate cancer disparities. Clin. Cancer Res. 21(21), pp. 4970–4984. 2015. DOI: 10.1158/1078–0432.CCR–14–1566.
[7] V. Ramesh and K. Ganesan. Integrative analysis of transcriptome and miRNome unveils the key regulatory connections involved in different stages of hepatocellular carcinoma. Genes Cells 21(9), pp. 949–965. 2016. DOI: 10.1111/gtc.12396.
[8] X. J. Tian, H. Zhang, J. Zhang and J. Xing. Reciprocal regulation between mRNA and microRNA enables a bistable switch that directs cell fate decisions. FEBS Lett. 590(19), pp. 3443–3455. 2016. DOI: 10.1002/1873–3468.12379.
[9] A. Valinezhad Orang, R. Safaralizadeh and M. Kazemzadeh-Bavili. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int. J. Genomics 2014pp. 970607. 2014. DOI: 10.1155/2014/970607.
[10]M. Denis and M. G. Tadesse. Evaluation of hierarchical models for integrative genomic analyses. Bioinformatics 32(5), pp. 738–746. 2016. DOI: 10.1093/bioinformatics/btv653.
[11]K. Kitagawa, G. Nakajima, H. Kuramochi, S. I. Ariizumi and M. Yamamoto. Lymphatic vessel endothelial hyaluronan receptor–1 is a novel prognostic indicator for human hepatocellular carcinoma. Mol. Clin. Oncol. 1(6), pp. 1039–1048. 2013. DOI: 10.3892/mco.2013.167.
[12] C. Meng, X. Shen and W. Jiang. Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncol. Lett. 16(3), pp. 3183–3192. 2018. DOI: 10.3892/ol.2018.9020.
[13] R. Chauhan and N. Lahiri. Tissue- and serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer. 8(Suppl 1), pp. 37–55. 2016. DOI: 10.4137/BIC.S34413.
[14] M. Lu, X. Kong, H. Wang, G. Huang, C. Ye and Z. He. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 8(5), pp. 8775–8784. 2017. DOI: 10.18632/oncotarget.14452.
[15] A. Nagy, A. Lanczky, O. Menyhart and B. Gyorffy. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8(1), pp. 9227–018–27521-y. 2018. DOI: 10.1038/s41598–018–27521-y.
[16] H. Sun, J. Song, C. Weng, J. Xu, M. Huang, Q. Huang, R. Sun, W. Xiao and C. Sun. Association of decreased expression of the macrophage scavenger receptor MARCO with tumor progression and poor prognosis in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 32(5), pp. 1107–1114. 2017. DOI: 10.1111/jgh.13633.
[17] S. A. MacParland, J. C. Liu, X. Z. Ma, B. T. Innes, A.M. Bartczak, B. K. Gage, J. Manuel, N. Khuu, J. Echeverri, I. Linares, R. Gupta, M. L. Cheng, L. Y. Liu, D. Camat, S. W. Chung, R. K. Seliga, Z. Shao, E. Lee, S. Ogawa, M. Ogawa, M. D. Wilson, J. E. Fish, M. Selzner, A. Ghanekar, D. Grant, P. Greig, G. Sapisochin, N. Selzner, N. Winegarden, O. Adeyi, G. Keller, G. D. Bader and I. D. McGilvray. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 9(1), pp. 4383–018–06318–7. 2018. DOI: 10.1038/s41467–018–06318–7.
[18] Q. Zhu, L. Gong, J. Wang, Q. Tu, L. Yao, J. R. Zhang, X. J. Han, S. J. Zhu, S. M. Wang, Y. H. Li and W. Zhang. miR–10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer 16(1), pp. 806–016–2801–4. 2016. DOI: 10.1186/s12885–016–2801–4.
[19] C. G. Liao, L. M. Kong, P. Zhou, X. L. Yang, J. G. Huang, H. L. Zhang and N. Lu. miR–10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs. J. Transl. Med. 12pp. 234–014–0234-x. 2014. DOI: 10.1186/s12967–014–0234-x.
[20] S. K. Narayana, K. J. Helbig, E. M. McCartney, N. S. Eyre, R. A. Bull, A. Eltahla, A. R. Lloyd and M. R. Beard. The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J. Biol. Chem. 290(43), pp. 25946–25959. 2015. DOI: 10.1074/jbc.M115.657346.
[21] M. Zhang, Q. Liu, S. Mi, X. Liang, Z. Zhang, X. Su, J. Liu, Y. Chen, M. Wang, Y. Zhang, F. Guo, Z. Zhang and R. Yang. Both miR–17–5p and miR–20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J. Immunol. 186(8), pp. 4716–4724. 2011. DOI: 10.4049/jimmunol.1002989.
[22] Y. Mano, S. Aishima, N. Fujita, Y. Tanaka, Y. Kubo, T. Motomura, A. Taketomi, K. Shirabe, Y. Maehara and Y. Oda. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 80(3), pp. 146–154. 2013. DOI: 10.1159/000346196.
[23] P. Yang, Q. J. Li, Y. Feng, Y. Zhang, G. J. Markowitz, S. Ning, Y. Deng, J. Zhao, S. Jiang, Y. Yuan, H. Y. Wang, S. Q. Cheng, D. Xie and X. F. Wang. TGF-beta-miR–34a-CCL22 signaling-induced treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer. Cell. 22(3), pp. 291–303. 2012. DOI: 10.1016/j.ccr.2012.07.023.
[24] N. Tsuji, S. Ishiguro, Y. Sasaki and M. Kudo. CD34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma. Dig. Dis. 31(5–6), pp. 467–471. 2013. DOI: 10.1159/000355246.
[25] J. S. Jing, H. Li, S. C. Wang, J. M. Ma, L. Q. Yu and H. Zhou. NDRG3 overexpression is associated with a poor prognosis in patients with hepatocellular carcinoma. Biosci. Rep. 38(6), pp. 10.1042/BSR20180907. Print 2018 Dec 21. 2018. DOI: BSR20180907.
[26] X. Zhang, J. Sheng, Y. Zhang, Y. Tian, J. Zhu, N. Luo, C. Xiao and R. Li. Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma. Oncotarget 8(65), pp. 109247–109257. 2017. DOI: 10.18632/oncotarget.22665.
[27] M. F. Li, J. J. Zeng, A. P. Pan, Y. H. Lin, H. S. Lin, R. Z. Zhang, L. Yang, Y. Zhang, Y. W. Dang and G. Chen. Investigation of miR–490–3p expression in hepatocellular carcinoma based on reverse transcription-polymerase chain reaction (RT-qPCR) and a meta-analysis of 749 cases. Med. Sci. Monit. 24pp. 4914–4925. 2018. DOI: 10.12659/MSM.908492.
[28] Y. Fang, J. L. Xue, Q. Shen, J. Chen and L. Tian. MicroRNA–7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/akt pathway in hepatocellular carcinoma. Hepatology 55(6), pp. 1852–1862. 2012. DOI: 10.1002/hep.25576.
[29] X. Liao, G. Zhu, R. Huang, C. Yang, X. Wang, K. Huang, T. Yu, C. Han, H. Su and T. Peng. Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma. Cancer. Manag. Res. 10pp. 787–803. 2018. DOI: 10.2147/CMAR.S161334.
[30] L. Liu, H. Yue, Q. Liu, J. Yuan, J. Li, G. Wei, X. Chen, Y. Lu, M. Guo, J. Luo and R. Chen. LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway. Oncotarget 7(13), pp. 15787–15800. 2016. DOI: 10.18632/oncotarget.7487.
[31] Y. Wang, Q. Huang, T. Deng, B. H. Li and X. Q. Ren. Clinical significance of TRMT6 in hepatocellular carcinoma: A bioinformatics-based study. Med. Sci. Monit. 25pp. 3894–3901. 2019. DOI: 10.12659/MSM.913556.
[32] E. Chen, X. Xu, R. Liu and T. Liu. Small but heavy role: MicroRNAs in hepatocellular carcinoma progression. Biomed. Res. Int. 2018pp. 6784607. 2018. DOI: 10.1155/2018/6784607.
[33] G. Bidkhori, R. Benfeitas, M. Klevstig, C. Zhang, J. Nielsen, M. Uhlen, J. Boren and A. Mardinoglu. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl. Acad. Sci. U.S. A. 115(50), pp. E11874-E11883. 2018. DOI: 10.1073/pnas.1807305115.
[34] C. J. Lin, H. Y. Gong, H. C. Tseng, W. L. Wang and J. L. Wu. miR–122 targets an anti-apoptotic gene, bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 375(3), pp. 315–20. 2008.
[35] S. Rudraiah, X. Zhang and L. Wang. Nuclear receptors as therapeutic targets in liver disease: Are we there yet? Annu. Rev. Pharmacol. Toxicol. 56pp. 605–626. 2016. DOI: 10.1146/annurev-pharmtox–010715–103209.
[36] M. L. Tornesello, L. Buonaguro, F. Izzo and F. M. Buonaguro. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget 7(18), pp. 25087–25102. 2016. DOI: 10.18632/oncotarget.7837.
[37] Cancer Genome Atlas Research Network. Electronic address: [email protected] and Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169(7), pp. 1327–1341.e23. 2017. DOI: S0092–8674(17)30639–6.
[38] C. V. Rao, A. S. Asch and H. Y. Yamada. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis 38(1), pp. 2–11. 2017. DOI: 10.1093/carcin/bgw118.
[39] J. Friedman, T. Hastie and R. Tibshirani. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw 33(1), pp. 1–22. 2010.